Details of the Drug Reposition

General Information of This Drug (ID: DMIMA4V)

Drug Name
BPX-501   DMIMA4V

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
6 Phase 1/2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Solid tumour/cancer DISZR48F 2A00-2F9Z Phase 1/2 [1]
Acute myeloid leukaemia DIS0BM1I 2A60 Phase 1/2 [1]
Acute lymphoblastic leukaemia DIS87TGM 2A85 Phase 1/2 [1]
Immunodeficiency DIS093I0 4A00-4A85 Phase 1/2 [2]
Osteoporosis DISF2JE0 FB83.0 Phase 1/2 [3]
Hematopoietic stem cell transplantation DISYL1E0 QB63 Phase 1/2 [4]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 Indications(s)

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 ClinicalTrials.gov (NCT01744223) Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant. U.S. National Institutes of Health.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)